Amperozide--a new putatively antipsychotic drug with a limbic mode of action on dopamine mediated behaviour.
Amperozide, a new putatively antipsychotic drug, was found to exert a functional selectivity for the limbic system of the brain. Thus, amperozide was as active as both classical and atypical neuroleptics on hypermotility induced by a low dose of amphetamine. On the other hand, amperozide did not produce catalepsy, nor did it reverse amphetamine-induced stereotypies. Moreover, amperozide inhibited exploratory behaviour in mice. The present results indicate an antipsychotic effect of amperozide, with a minimal risk for EPS when used in the clinic.
Gustafsson
B
B
Dept of CNS-research, Pharmacia LEO Therapeutics AB, Malmö, Sweden.
Christensson
E
E
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects* / Q000502:physiology; D002375:Catalepsy / Q000139:chemically induced; D003913:Dextroamphetamine / Q000494:pharmacology; D004298:Dopamine / Q000502:physiology*; D005106:Exploratory Behavior / Q000187:drug effects; D005260:Female; D008032:Limbic System / Q000187:drug effects*; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D010879:Piperazines / Q000494:pharmacology*; D011619:Psychotropic Drugs / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D013239:Stereotyped Behavior / Q000187:drug effects
D014150:Antipsychotic Agents; D010879:Piperazines; D011619:Psychotropic Drugs; C049058:amperozide; D003913:Dextroamphetamine; D004298:Dopamine